Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · IEX Real-Time Price · USD
11.24
+0.03 (0.27%)
May 2, 2024, 4:00 PM EDT - Market closed
Roivant Sciences Employees
Roivant Sciences had 904 employees on March 31, 2023. The number of employees increased by 41 or 4.75% compared to the previous year.
Employees
904
Change (1Y)
41
Growth (1Y)
4.75%
Revenue / Employee
$136,329
Profits / Employee
$4,940,735
Market Cap
9.06B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2023 | 904 | 41 | 4.75% |
| Mar 31, 2022 | 863 | 198 | 29.77% |
| Jun 30, 2021 | 665 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Encompass Health | 37,761 |
| Henry Schein | 25,000 |
| Chemed | 15,087 |
| Teleflex | 14,500 |
| AptarGroup | 13,800 |
| Qiagen | 5,967 |
| Stevanato Group | 5,634 |
| Legend Biotech | 1,826 |
ROIV News
- 7 days ago - Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis - Business Wire
- 4 weeks ago - Roivant's anti-inflammatory drug succeeds in mid-stage study - Reuters
- 4 weeks ago - Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million - GlobeNewsWire
- 2 months ago - Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update - GlobeNewsWire
- 4 months ago - Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease - GlobeNewsWire
- 5 months ago - Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease - GlobeNewsWire
- 5 months ago - Roivant Sciences shares drop as lupus treatment misses trial goal - Market Watch
- 5 months ago - Roivant Sciences' lupus drug fails to reduce symptoms in mid-stage study - Reuters